# Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in HIV+ Patients With Non-Infectious Diarrhea

> **NCT04192487** · PHASE4 · COMPLETED · sponsor: **Napo Pharmaceuticals, Inc.** · enrollment: 17 (actual)

## Conditions studied

- Acquired Immunodeficiency Syndrome
- Healthy Volunteers
- HIV/AIDS
- HIV Diarrhea
- Human Immunodeficiency Virus

## Interventions

- **DRUG:** Crofelemer delayed-release tablets 125mg

## Key facts

- **NCT ID:** NCT04192487
- **Lead sponsor:** Napo Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-22
- **Primary completion:** 2021-08-31
- **Final completion:** 2021-08-31
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2021-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04192487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04192487, "Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in HIV+ Patients With Non-Infectious Diarrhea". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04192487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*